A recent meta-analysis showed that the median progression-free survival (PFS) was only 3.4 months, while the overall survival (OS)—10 months in real-world settings, with PD-1/PD-L1 inhibitors as the second-line therapy in advanced and metastatic NSCLC [2]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.